Titre :

Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.

Auteur(s) :

Vieujean, Sophie [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Laharie, David [Auteur]

Buisson, Anthony [Auteur]
CHU Clermont-Ferrand
Roblin, Xavier [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Fumery, Mathurin [Auteur]
Université de Picardie Jules Verne [UPJV]
Nancey, Stephane [Auteur]
Hospices Civils de Lyon [HCL]
Wils, Pauline [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Altwegg, Romain [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Seidel, Laurence [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Caron, Bénédicte [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]

Titre de la revue :

Digestive and Liver Disease

Nom court de la revue :

Dig Liver Dis

Date de publication :

2023-12-11

ISSN :

1878-3562

Résumé en anglais : [en]

Background: While the efficacy of tofacitinib to induce and maintain clinical and endoscopic remission is well established in ulcerative colitis (UC), little is known about its efficacy to induce histological remission. ...
Lire la suite >Background: While the efficacy of tofacitinib to induce and maintain clinical and endoscopic remission is well established in ulcerative colitis (UC), little is known about its efficacy to induce histological remission. Methods: We conducted a retrospective multicentric cohort study. UC patients ≥ 16 years treated by tofacitinib in whom histological activity has been evaluated before and after induction were eligible. The primary endpoint was the histological remission at the end of induction, assessed by the Nancy index and the epithelial neutrophilic infiltrate. Results: A total of 42 patients with UC (93% previously exposed to an anti-TNF and 81% to vedolizumab) were included between July 2018 and April 2022 and were followed for a median duration of 84 weeks [IQR, 35-134]. At the end of induction period (whether prolonged or not), 19% and 24% of patients achieved histological remission, using the Nancy index and the epithelial neutrophilic infiltrate, respectively. Survival without tofacitinib discontinuation was significantly longer in patients without epithelial neutrophilic infiltrate at the end of induction (whether prolonged or not) compared with patients with epithelial neutrophilic infiltrate (p = 0.036). Conclusion: Tofacitinib induced histological remission in one fifth to one quarter of patients with UC who have previously failed anti-TNF or/and vedolizumab after induction (whether prolonged or not).Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-02-01T22:02:28Z
2024-03-11T15:36:18Z